Five more biotechs file their SEC pa­per­work as the IPO Class of 2021 swells to 60

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Af­ter last week’s flur­ry of IPO ac­tion end­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.